An Anglesey man wants to know why it took so long for Betsi health chiefs to start treatment on his "aggressive cancer" - a ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...

The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation by Dr. Laurence Klotz discussing initial perioperative outcomes of CAPTAIN, ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT, is reinforcing its position as a leading provider of advanced imaging and guided ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests. The imaging test highlights aggressive prostate cancer cells, reducing the ...

First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...